Hunan Er Kang Pharmaceutical (300267) - Net Assets
Based on the latest financial reports, Hunan Er Kang Pharmaceutical (300267) has net assets worth CN¥4.42 Billion CNY (≈ $646.12 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.05 Billion ≈ $738.96 Million USD) and total liabilities (CN¥634.44 Million ≈ $92.84 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Hunan Er Kang Pharmaceutical PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.42 Billion |
| % of Total Assets | 87.44% |
| Annual Growth Rate | 30.4% |
| 5-Year Change | -24.02% |
| 10-Year Change | 3.4% |
| Growth Volatility | 122.79 |
Hunan Er Kang Pharmaceutical - Net Assets Trend (2008–2024)
This chart illustrates how Hunan Er Kang Pharmaceutical's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 300267 market cap.
Annual Net Assets for Hunan Er Kang Pharmaceutical (2008–2024)
The table below shows the annual net assets of Hunan Er Kang Pharmaceutical from 2008 to 2024. Also explore 300267 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.40 Billion ≈ $644.18 Million |
-8.48% |
| 2023-12-31 | CN¥4.81 Billion ≈ $703.86 Million |
-4.77% |
| 2022-12-31 | CN¥5.05 Billion ≈ $739.13 Million |
+3.64% |
| 2021-12-31 | CN¥4.87 Billion ≈ $713.18 Million |
-15.88% |
| 2020-12-31 | CN¥5.79 Billion ≈ $847.78 Million |
+0.01% |
| 2019-12-31 | CN¥5.79 Billion ≈ $847.71 Million |
+2.73% |
| 2018-12-31 | CN¥5.64 Billion ≈ $825.21 Million |
+4.21% |
| 2017-12-31 | CN¥5.41 Billion ≈ $791.90 Million |
+3.19% |
| 2016-12-31 | CN¥5.24 Billion ≈ $767.41 Million |
+23.19% |
| 2015-12-31 | CN¥4.26 Billion ≈ $622.97 Million |
+153.72% |
| 2014-12-31 | CN¥1.68 Billion ≈ $245.53 Million |
+25.78% |
| 2013-12-31 | CN¥1.33 Billion ≈ $195.21 Million |
+14.58% |
| 2012-12-31 | CN¥1.16 Billion ≈ $170.37 Million |
+9.60% |
| 2011-12-31 | CN¥1.06 Billion ≈ $155.44 Million |
+501.44% |
| 2010-12-31 | CN¥176.62 Million ≈ $25.85 Million |
+60.55% |
| 2009-12-31 | CN¥110.01 Million ≈ $16.10 Million |
+74.60% |
| 2008-12-31 | CN¥63.01 Million ≈ $9.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Er Kang Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4787.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.17 Billion | 26.22% |
| Other Components | CN¥3.28 Billion | 73.78% |
| Total Equity | CN¥4.45 Billion | 100.00% |
Hunan Er Kang Pharmaceutical Competitors by Market Cap
The table below lists competitors of Hunan Er Kang Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KCTech Co Ltd
KO:281820
|
$971.99 Million |
|
Retail Estates - Sicafi
BR:RET
|
$972.21 Million |
|
Quantum Corporation
NASDAQ:QMCO
|
$972.64 Million |
|
Beijing Asiacom Information Technology Co.Ltd
SHE:301085
|
$972.67 Million |
|
GIGAVIS LTD (PROPOSED)
KQ:420770
|
$971.55 Million |
|
Mega Lifesciences Public Company Limited
BK:MEGA
|
$971.52 Million |
|
Pacira BioSciences, Inc.
NASDAQ:PCRX
|
$971.50 Million |
|
ZYNP Corp
SHE:002448
|
$971.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Er Kang Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,836,045,778 to 4,447,425,532, a change of -388,620,246 (-8.0%).
- Net loss of 373,371,436 reduced equity.
- Dividend payments of 8,415,180 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-373.37 Million | -8.4% |
| Dividends Paid | CN¥8.42 Million | -0.19% |
| Other Changes | CN¥-6.83 Million | -0.15% |
| Total Change | CN¥- | -8.04% |
Book Value vs Market Value Analysis
This analysis compares Hunan Er Kang Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.49x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.24x to 1.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥2.60 | CN¥3.22 | x |
| 2018-12-31 | CN¥2.71 | CN¥3.22 | x |
| 2019-12-31 | CN¥2.79 | CN¥3.22 | x |
| 2020-12-31 | CN¥2.80 | CN¥3.22 | x |
| 2021-12-31 | CN¥2.35 | CN¥3.22 | x |
| 2022-12-31 | CN¥2.45 | CN¥3.22 | x |
| 2023-12-31 | CN¥2.34 | CN¥3.22 | x |
| 2024-12-31 | CN¥2.16 | CN¥3.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Er Kang Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -32.76%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 1.17x
- Recent ROE (-8.40%) is below the historical average (9.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 17.77% | 8.60% | 1.03x | 2.01x | CN¥4.74 Million |
| 2009 | 20.92% | 14.41% | 0.85x | 1.71x | CN¥11.87 Million |
| 2010 | 37.93% | 18.26% | 1.23x | 1.69x | CN¥48.94 Million |
| 2011 | 11.12% | 19.36% | 0.54x | 1.06x | CN¥11.83 Million |
| 2012 | 13.12% | 18.20% | 0.67x | 1.07x | CN¥36.13 Million |
| 2013 | 14.54% | 19.09% | 0.70x | 1.09x | CN¥60.25 Million |
| 2014 | 17.78% | 21.95% | 0.59x | 1.37x | CN¥126.12 Million |
| 2015 | 14.45% | 39.18% | 0.32x | 1.15x | CN¥186.21 Million |
| 2016 | 19.81% | 34.67% | 0.52x | 1.09x | CN¥508.17 Million |
| 2017 | 9.74% | 18.48% | 0.49x | 1.07x | CN¥-14.21 Million |
| 2018 | 3.87% | 9.20% | 0.39x | 1.08x | CN¥-343.32 Million |
| 2019 | 2.80% | 5.89% | 0.45x | 1.07x | CN¥-414.36 Million |
| 2020 | 3.51% | 8.49% | 0.36x | 1.14x | CN¥-374.42 Million |
| 2021 | -16.31% | -35.40% | 0.41x | 1.12x | CN¥-1.28 Billion |
| 2022 | 0.91% | 2.45% | 0.32x | 1.16x | CN¥-459.32 Million |
| 2023 | -4.04% | -10.95% | 0.33x | 1.13x | CN¥-678.93 Million |
| 2024 | -8.40% | -32.76% | 0.22x | 1.17x | CN¥-818.11 Million |
Industry Comparison
This section compares Hunan Er Kang Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Er Kang Pharmaceutical (300267) | CN¥4.42 Billion | 17.77% | 0.14x | $971.87 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Hunan Er Kang Pharmaceutical
Hunan Er-Kang Pharmaceutical Co., Ltd manufactures and sells APIs, finished drug products, and pharmaceutical excipients in China and internationally. Its APIs include glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's finished drugs primarily comprise sulbenicillin sodium for i… Read more